Drug General Information
Drug ID	D0H7XJ
Former ID	DIB002791
Drug Name	ASP-9521
Indication	Prostate cancer [ICD9: 185; ICD10:C61]		Phase 1/2	[523469]
Company	Astellas Pharma Inc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Aldo-keto reductase family 1 member C3	Target Info	Modulator	[532753], [532866]
BioCyc Pathway	Superpathway of steroid hormone biosynthesis
	Allopregnanolone biosynthesis
	Androgen biosynthesis
KEGG Pathway	Steroid hormone biosynthesis
	Arachidonic acid metabolism
	Metabolic pathways
	Ovarian steroidogenesis
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway	Arachidonic Acid Metabolism
Reactome	Retinoid metabolism and transport
WikiPathways	Metapathway biotransformation
	Benzo(a)pyrene metabolism
	Arachidonic acid metabolism
References
Ref 523469	ClinicalTrials.gov (NCT01352208) Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients. U.S. National Institutes of Health.
Ref 532753	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
Ref 532866	In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; AKR1C3). Invest New Drugs. 2014 Oct;32(5):860-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.